Loading
Building a genetically engineered mouse for a specific cancer takes years. Editing genes directly in an adult mouse's organ can produce the same tumour in weeks.
Somatic genome editing by electroporation, viral delivery or lipid nanoparticles into a target organ produces autochthonous tumours with intact immune systems and native microenvironment, at a fraction of the time and cost of germline models. This has been demonstrated in lung, pancreas, liver and brain. Combinatorial guide libraries also allow genotype-response mapping in immunocompetent animals.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Lab models that fail to predict what happens in patients, Pancreatic ductal adenocarcinoma.
Shares Estimation of clinical trial success rates and related parameters, CRISPR functional genomics, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Lab models that fail to predict what happens in patients.
Shares Patient-derived xenografts, CRISPR functional genomics, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Lab models that fail to predict what happens in patients.